BG Medicine Receives Federal QTDP Grant

WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine, Inc., a U.S.-based life sciences company, today announced it has been awarded $488,958 in Qualifying Therapeutic Discovery Project (QTDP) grants from the U.S. Government based on the company’s 2009 research related to the development of the BGM Galectin-3 blood test, a test to identify high risk patients with cardiovascular disease and myocardial fibrosis, and AMIPredict™, a test to identify patients with a high risk of suffering a near-term heart attack or stroke. The QTDP program was created as part of the health care reform legislation passed earlier this year.